Greenwood Capital Associates LLC Sells 898 Shares of Danaher Corporation $DHR

Greenwood Capital Associates LLC reduced its stake in Danaher Corporation (NYSE:DHR) by 14.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,499 shares of the conglomerate’s stock after selling 898 shares during the period. Greenwood Capital Associates LLC’s holdings in Danaher were worth $1,086,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. NBC Securities Inc. bought a new stake in shares of Danaher during the first quarter valued at about $176,000. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in Danaher by 26.9% in the 1st quarter. Thurston Springer Miller Herd & Titak Inc. now owns 5,914 shares of the conglomerate’s stock valued at $1,212,000 after purchasing an additional 1,252 shares during the period. Vest Financial LLC boosted its holdings in Danaher by 73.6% in the 1st quarter. Vest Financial LLC now owns 5,361 shares of the conglomerate’s stock valued at $1,099,000 after purchasing an additional 2,273 shares during the period. Fjell Capital LLC grew its position in shares of Danaher by 20.6% during the 1st quarter. Fjell Capital LLC now owns 2,386 shares of the conglomerate’s stock valued at $489,000 after purchasing an additional 408 shares in the last quarter. Finally, Curat Global LLC bought a new position in shares of Danaher in the first quarter worth $219,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 2.2%

Shares of DHR opened at $215.05 on Friday. The firm has a market cap of $153.98 billion, a P/E ratio of 45.75, a P/E/G ratio of 3.00 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.41. The stock has a 50 day simple moving average of $200.19 and a two-hundred day simple moving average of $197.42.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 27.23%.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on DHR shares. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Bank of America lowered their price target on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research note on Saturday, September 27th. Wells Fargo & Company cut their price target on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 23rd. Finally, UBS Group cut their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $245.91.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.